subject: Vision Shopsters: Neuropathic Pain: Competing Treatments and Market Entry Considerations [print this page] Vision Shopsters: Neuropathic Pain: Competing Treatments and Market Entry Considerations
This report presents the findings of a global study of current therapeutic approaches to the treatment of Neuropathic Pain (NP). These findings were made following the participation of more than 330 clinics, who provided details of their treatments and prescribing practices. This was carried out as part of a competitor insight and market entry study, in the neuropathic pain field.
With estimated prevalence levels of 3-10%, the treatment of Neuropathic Pain (NP) remains an area of significant unmet need. NP is highly individual in its presentation, level, underlying pathology and response to therapy. For some patients, available therapies give satisfactory pain control. For many others, treatments are poor or do not work at all. Therapeutic options include more than ten drug classes, which are commonly prescribed in combinations tailored to individual patient needs.
Overview :
Comprehensive details of current treatments for NP, provided by more than 330 clinics in 56 countries
In-depth information relevant to markets and opportunities in the NP field
98% of participants are practicing physicians, working in specialised areas of pain treatment. Of these, 78% described themselves as specialists in pain treatment
Leading participant countries were USA, Canada, UK, Australia, Denmark, France, Brazil, Germany, Netherlands and Belgium
74% of the clinical centres participating in this study were hospital pain departments, specialised pain practices or private pain clinics. Detailed information on the use of specific drug classes including tricyclic antidepressants, SSRIs, SNRIs, anticonvulsants, sodium channel blockers, opioids, NSAIDS, cannabinoids and Capsaicin
Physicians have provided detailed feedback on the underlying pathologies associated with NP, seen in their patients
Comprehensive information on the most frequently prescribed drugs from nine drugs classes, including drug combinations, for the treatment of NP. Biopharm Reports believes this provides the most comprehensive and up-to-date review and analysis in this area, currently available
A detailed analysis of interventional methods used for the treatment of NP (e.g. peripheral nerve block, TENS)
An assessment of average levels of pain relief achieved in the treatment of NP, in relation to 12 underlying conditions
Informative views of participating physicians on current limitations, challenges and issues relating to the treatment of NP
For more information on the report, kindly visit :
